Navigation Links
Seambiotic Appoints New CEO
Date:9/14/2009

ASHKELON, Israel, Sept. 14 /PRNewswire/ -- Seambiotic, a global leader in the development and production of marine microalgae for the nutraceuticals and biofuel industries, has announced that Daniel Chinn has been appointed Chief Executive Officer of the company effective immediately. Daniel replaces founder and previous CEO Amnon Bechar who has been appointed to a new role of Chief Operating Officer.

Daniel joins Seambiotic following a career in law and venture capital. Following a law degree at University College, Oxford University, Daniel started his professional career at Herzog, Fox & Neeman where he spent 12 years, ending his time there as an M&A partner in the international department specializing in representation of multinational corporations. In 2000, Daniel joined Israel Seed Partners, an Israeli venture capital fund with close to $300M under management.

"I am very excited about joining Seambiotic at this turning point in its development," said Chinn. "Seambiotic has proven its model for microalgae cultivation and has been inundated with requests for partnerships and joint projects. I hope that I will be able to help Seambiotic move smoothly through the next phases of its growth as it becomes a major player in the industry."

Seambiotic (http://www.seambiotic.com/) was founded in 2003 to grow and process marine microalgae for the nutraceutical and biofuel industries. Seambiotic's research efforts include a pilot study at an Israeli Electric Corporation power station near the city Ashkelon, Israel, where various species of marine microalgae have been successfully cultivated using the power station's CO2 emissions released directly from their smokestacks; the microalgae are in turn sold into the nutraceutical market or used as feedstock for animal or fish and biofuel. Seambiotic's technology reduces the cost of microalgae production significantly while lowering global warming by reducing industrial CO2 emissions. The company is currently in transition from the pilot plant stage to commercial scale algae cultivation and production.

    Contact:
    Osnat Dobzinski
    Seambiotic Ltd.
    Tel:  +972 3 6911 688
    Email: osnat@seambiotic.com


'/>"/>
SOURCE Seambiotic Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Seambiotic USA and NASA Glenn Research Center Signed Agreement for Large Scale Microalgae Process Optimization
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... announced the three Winners and six Finalists of the 2017 Blavatnik Regional Awards ... the Blavatnik Family Foundation and administered by the New York Academy of Sciences ...
(Date:10/12/2017)... ... ... AMRI, a global contract research, development and manufacturing organization ... quality of life, will now be offering its impurity solutions as a stand-alone ... for all new drug products, including the finalization of ICH M7 earlier this ...
(Date:10/11/2017)... Wayne. NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a ... rinse one eye at a time. So which eye do you rinse first if a ... you have Plum Duo Eye Wash with its unique dual eye piece. , ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
Breaking Biology Technology:
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):